Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on. [Read More]
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. [Read More]
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. [Read More]
BTI GmbH was founded in 2013 as a linkage between academia and industry. With the vision to provide a robust and versatile enzyme-based conjugation platform BTI developed its novel TrypCo® technology enabling efficient N- or C-terminal modification of basically any protein with a virtually unlimited variety of artificial functionalities like fluorescent probes, toxins or polymers. TrypCo® features a fast and efficient one-step labeling procedure under mild reaction conditions without the need of co-factors or special agents. This highlights TrypCo® as an ideal tool for the generation of site-specifically conjugated ADC´s. www.trypco.de
CARBOGEN AMCIS combines world-class chemistry skills to provide seamless drug development and commercialization services for pharmaceutical and biotechnology companies. Through our customized offering we provide an array of integrated process research and manufacturing services to support the fast supply of complex Antibody Drug Conjugates (ADCs). Our infrastructure is fully cGMP compliant and includes a clean room dedicated to ADCs in Switzerland and a formulation site with lyophilization capabilities in France.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of chemical and biological APIs for its partners world-wide.
Exclusive, CDMO services are offered for the development and manufacturing of HPAIs and ADCs payloads as well as for biological products including ADCs, monoclonal antibodies and Recombinant Proteins.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs.
Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
Iksuda Therapeutics (formally Glythera) is a pre-clinical stage company developing ADCs for difficult to treat solid tumours. Our ADCs are centered around our proprietary PermaLInk® conjugation platform which provides conjugation stability by design.Through PermaLink, we aim to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA damaging payloads, combined with clinically relevant targets.Through our collaborations and partnerships, we are building a pipeline of superior ADCs with the goal of improving the lives of patients living with cancer. www.iksuda.com